Association of CD4 count and HIV viral load with risk of Non-AIDS-defining cancers
Menée aux Etats-Unis auprès de 10 413 patients infectés par le VIH, cette étude analyse l'association entre la charge virale, le taux de lymphocytes CD4+ et le risque de développer un cancer non lié au SIDA
Objectives: HIV-induced immunodeficiency contributes to an increased risk of non-AIDS-defining cancers (NADC). This study aims to identify the most predictive viral load (VL) or CD4 measures of NADC risk among people living with HIV (PLWH). Design: Extracted from South Carolina electronic HIV reporting system, we studied adult PLWH who were cancer-free at baseline and had at least 6 months of follow-up since HIV diagnosis between January 2005 and December 2020. Methods: Using multiple proportional hazards models, risk of NADC was investigated in relation to twelve measures of VL and CD4 at three different time intervals before NADC diagnosis. The best VL/CD4 predictor(s) and final model were determined using Akaike's information criterion. Results: Among 10,413 eligible PLWH, 449 (4.31%) developed at least one type of NADC. After adjusting for potential confounders, the best predictors of NADC were the proportion of days with viral suppression (hazard ratio [HR]: 0.47 (>25% and ≤50% vs =0), 95% confidence interval [CI]: [0.28, 0.79]) and proportion of days with low CD4 count (AIC = 7201.35) (HR: 12.28 (>75% vs = 0), 95% CI: [9.29, 16.23]). Conclusions: VL and CD4 measures are strongly associated with risk of NADC. In analyses examining three time windows, proportion of days with low CD4 count was the best CD4 predictor for each time window. However, the best VL predictor varied across time windows. Thus, using the best combination of VL and CD4 measures for a specific time window should be considered when predicting NADC risk.
AIDS 2023